The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study group.
Fertility-sparing surgery
Ovarian germ cell tumors
Quality of life
Sex cord stromal tumors
Sexuality
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
12
12
2020
accepted:
23
02
2021
pubmed:
22
7
2021
medline:
26
11
2021
entrez:
21
7
2021
Statut:
ppublish
Résumé
Malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST) are ovarian neoplasms that affect disproportionally young women. Little is known about the impact of surgical and adjuvant management of these patient's sexual life. This study investigated the effect of fertility-sparing surgery on sexual activity and global quality of life (gQoL) in women with MOGCT and SCST. CORSETT was an observational, multicenter, mixed retrospective/prospective cohort study of the AGO study group. Women of any age who had been diagnosed with MOGCTs and SCSTs between 2001 and 2011 were asked to complete the Sexual Activity Questionnaire (SAQ) and the EORTC QLQ-C30. In total, 355 patients were included. Of these, 152 patients with confirmed histological diagnosis had completed the questionnaires. A total of 106 patients were diagnosed with SCST and 46 with MOGCT. Totally, 83 women (55%) were sexually active. After fertility-sparing surgery, patients had a 2.6 fold higher probability for being sexually active than after non-fertility-conserving treatment (unadjusted odds ratio (OR) 2.6, p = 0.01). After adjustment for age, time since diagnosis, FIGO stage, histology and phase of disease, the OR dropped to 1.8 (p = 0.22). Of the sexually active patients, 35 (42%) reported high levels of discomfort during intercourse; 38% after fertility-sparing; and 58% after non-fertility-sparing surgery (adjusted OR 2.8, p = 0.18). Women with fertility-conserving treatment reported a significantly better global QoL (F Fertility preserving approaches should be offered to every patient, when oncologically acceptable.
Identifiants
pubmed: 34287678
doi: 10.1007/s00404-021-06019-5
pii: 10.1007/s00404-021-06019-5
pmc: PMC8553700
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1541-1549Informations de copyright
© 2021. The Author(s).
Références
Gynecol Oncol. 2016 Nov;143(2):428-432
pubmed: 27569583
Qual Life Res. 1996 Feb;5(1):81-90
pubmed: 8901370
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S48-54
pubmed: 25341580
Gynecol Oncol. 2001 Dec;83(3):537-42
pubmed: 11733968
Br J Cancer. 2003 Mar 10;88(5):666-71
pubmed: 12618871
Int J Gynecol Cancer. 2020 Oct;30(10):1548-1553
pubmed: 32938723
Gynecol Oncol. 2017 Feb;144(2):405-413
pubmed: 27931752
Gynecol Oncol. 2008 Feb;108(2):348-54
pubmed: 17996925
Obstet Gynecol Clin North Am. 2006 Dec;33(4):621-30, ix
pubmed: 17116505
Gynecol Oncol. 2005 Oct;99(1):248-50
pubmed: 16095676
Pediatr Blood Cancer. 2018 Dec;65(12):e27396
pubmed: 30216642
Fertil Steril. 1994 Jul;62(1):20-7
pubmed: 8005293
Cancer. 2018 Jan 1;124(1):176-182
pubmed: 28881456
Dtsch Arztebl Int. 2020 Sep 25;117(39):645-652
pubmed: 33357344
Ann Oncol. 2012 Oct;23 Suppl 7:vii20-6
pubmed: 22997450
J Clin Endocrinol Metab. 2005 Jul;90(7):3847-53
pubmed: 15827095
Gynecol Oncol. 2020 Jun;157(3):693-699
pubmed: 32223987
Int J Gynecol Cancer. 2018 Nov;28(9):1737-1742
pubmed: 30358703
Gynecol Oncol. 2017 Dec;147(3):493-496
pubmed: 29021083
Int J Gynaecol Obstet. 1996 Oct;55(1):1-10
pubmed: 8910077
J Clin Endocrinol Metab. 2000 Aug;85(8):2832-8
pubmed: 10946891
Gynecol Oncol. 2017 Jun;145(3):513-518
pubmed: 28372870